BFRI earnings: next report 2026-08-12, real EPS beat/miss history, analyst consensus Buy, P/E -0.96. Updated 2026-07-23.
Biofrontera (BFRI) Research Hub
Biofrontera (BFRI) trades on NASDAQ, US in the Healthcare (Medical - Pharmaceuticals) sector. As of 2026-09-11, shares last closed at 1.55 USD (+0.65%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.96, market cap 0.01B. This hub links to the full technical, earnings and options research available for BFRI.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Pharmaceuticals) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.55 USD (+0.65%) |
| 52-week range | 0.867 USD – 1.66 USD |
| Trend regime | Range |
| 14-day RSI | 70.6 (Overbought) |
| Trailing P/E | -0.96 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-12 |
Available research for BFRI
Covered Call on BFRI: how it works, illustrative setup around the real 1.55 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BFRI: how it works, illustrative setup around the real 1.55 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BFRI: how it works, illustrative setup around the real 1.55 USD price, max profit/loss, breakeven and when to use it. Educational.
BFRI technical analysis: range, last 1.55 USD, RSI 70.6, 52w range 0.867 USD–1.66 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is BFRI in?
Biofrontera (BFRI) is classified under Healthcare (Medical - Pharmaceuticals), listed on NASDAQ, US.
Is BFRI in an uptrend or downtrend?
As of 2026-09-11, BFRI is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BFRI's trailing P/E ratio?
BFRI's trailing P/E is -0.96, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does BFRI next report earnings?
BFRI is next scheduled to report earnings on 2026-08-12, with a consensus EPS estimate of -0.105 USD.